Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Increased risk of osteoporosis following commonly used first-line treatments for lymphoma: a Danish Nationwide Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Increased risk of osteoporosis following commonly used first-line treatments for lymphoma: a Danish Nationwide Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Increased risk of anemia, neutropenia and thrombocytopenia in people with HIV and well-controlled viral replication

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Blodsygdomme

    Research output: Chapter in Book/Report/Conference proceedingBook chapterCommunication

View graph of relations

In this study, we analyzed the evolution of the prognosis of primary central nervous system lymphoma (PCNSL) patients as they reach selected progression-free survival (PFS) milestones after high-dose methotrexate (HD-MTX)-based therapy. In total, 258 and 146 patients were included from Denmark and British Columbia, respectively. All patients were diagnosed during 2000-2017. The 5-year PFS was 27% (95% CI 23; 32); however, for patients reaching 5 years of PFS, this increased to 71% (95% CI 57; 86). Within the first 5 years after diagnosis, patients lost 2.0 years (95% CI 1.8; 2.2) when compared to a similar background population. This reduced to 0.5 years (95% CI 0.2; 0.9) for patients reaching 5 years of PFS. Treatment with rituximab was associated with improved outcomes. The prognosis of patients with PCNSL treated with HD-MTX-based regimens in this cohort is poor, although it improves as patients survive without progression/relapse. However, survival does not conclusively normalize to that of a similar background population.

Original languageEnglish
JournalLeukemia and Lymphoma
Volume60
Issue number10
Pages (from-to)2516-2523
Number of pages8
ISSN1042-8194
DOIs
Publication statusPublished - Oct 2019

ID: 59260620